• ru
  • en

+7 (495) 782-23-42

  • Home
  • About us
  • Team
    • Management team
    • Advisory Board
  • Portfolio companies
    • Exited investments
    • Current investments
  • News
  • Contact

News

Home / News

RetroSense Therapeutics Doses First Patient in Phase I/II Clinical Trial for Lead Compound RST-001

21.03.2016

Clinical trial to assess the safety and, potentially efficacy, of novel gene therapy application of optogenetics in patients with retinitis pigmentosa

More

RBV Capital Wins The New Player Of The Year Nomination From The Venture Awards Russia 2015

09.12.2015

At the Venture Awards Russia 2015 ceremony, December 5, Russia’s first VC award went to RBV Capital in the New Player of the Year nomination.

More

RetroSense Therapeutics Raises $6 million in an Over-­Subscribed Series B Financing to Advance Clinical Development of Lead Product RST­‐001 for Retinitis Pigmentosa

16.11.2015

Patient recruitment underway for Phase I/II clinical study RetroSense Therapeutics, a privately­‐held, clinical-stage biopharmaceutical company, today announced that it has secured $6 million in a Series B financing to further investigate the use of gene therapy and optogenetics to restore vision.

More

Poistion: Investment analyst/manager

07.09.2015

The managing company of RBV Capital has an open position for an investment analyst/manager. Background/education in medicine, biotech or life sciences, investment experience in pharma/healthcare, work experience in pharma companies or other relevant experience very welcome.

More

Image Analysis Ltd. secures $5.2m from RBV Capital

25.05.2015

LONDON, United Kingdom, April 27, 2015 – Image Analysis Limited, a privately-held digital health software and services provider of medical imaging analysis in clinical trials and daily clinical practice, has completed a $5.2m venture financing with Danish Research Foundation (DRF) and RBV Capital.

More
Previous
Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13

All rights to the materials of this website are held by the partners of the RusBio Ventures Limited Partnership (Investment Partnership Agreement dated 10 October 2014)